US Stock MarketDetailed Quotes

GOSS Gossamer Bio

Watchlist
  • 1.140
  • -0.040-3.39%
Trading Mar 4 10:33 ET
258.33MMarket Cap-4.56P/E (TTM)

About Gossamer Bio Company

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Company Profile

SymbolGOSS
Company NameGossamer Bio
Listing DateFeb 8, 2019
Issue Price16.00
Founded2015
CEOMr. Faheem Hasnain
MarketNASDAQ
Employees135
Fiscal Year Ends12-31
Address3013 Science Park Road,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-684-1300

Company Executives

  • Name
  • Position
  • Salary
  • Faheem Hasnain
  • Chairman of the Board, President and Chief Executive Officer
  • 2.10M
  • Bryan Giraudo
  • Chief Operating Officer, Chief Financial Officer and Principal Accounting Officer
  • 1.29M
  • Bob Smith
  • Chief Commercial Officer
  • 1.33M
  • Dr. Richard Aranda, M.D.
  • Chief Medical Officer
  • --
  • Christian Waage
  • Executive Vice President, Technical Operations and Administration
  • --
  • Caryn Peterson
  • Executive Vice President, Regulatory Affairs
  • --
  • Dr. Sandra Milligan, J.D.
  • Independent Director
  • 81.82K
  • Skye Drynan
  • Independent Director
  • --
  • Russell J. Cox
  • Independent Director
  • 87.32K
  • Dr. Thomas O. Daniel, M.D.
  • Lead Independent Director
  • 98.82K
  • Dr. John D. Quisel, J.D.,PhD
  • Independent Director
  • 133.61K
  • Dr. Steven Nathan, M.D.
  • Independent Director
  • --

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More